Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXCR4


Brief Information

Name:C-X-C motif chemokine receptor 4
Target Synonym:NPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CX4-H5219 Human Human CXCR4 / CD184 Full Length Protein-VLP (HEK293)
CX4-H5269 Human Human CXCR4 / CD184 Protein, Fc Tag

Part of Bioactivity data


Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).

Synonym Name



C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Plerixafor SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 Approved Genzyme Corp Mozobil, Mobozil, 释倍灵 Mainland China Lymphoma, Non-Hodgkin; Multiple Myeloma Genzyme Europe Bv 2008-12-15 Multiple Myeloma; Anemia, Sickle Cell; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Pulmonary Disease, Chronic Obstructive; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Brain Neoplasms; Neuroblastoma; Sarcoma, Ewing; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of organ transplantation; Pulmonary Fibrosis; Hematologic Neoplasms; beta-Thalassemia; Kidney Diseases; Myeloproliferative Disorders; Hodgkin Disease; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Neutropenia; Solid tumours; Cystic Fibrosis; Hematopoietic stem cell transplantation (HSCT); Bone metastases; Leukemia; Bone Marrow Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
X-4136 X-4136 Clinical X4 Pharmaceuticals Lymphoma, B-Cell Details
4-P-021 4P021; 4-P-021 Phase 2 Clinical University of Bordeaux, Institut Pasteur De Lille Coronavirus Disease 2019 (COVID-19) Details
NRP-2945 NNZ-4945; NRP-2945 Phase 2 Clinical Neuren Pharmaceuticals Epilepsy Details
AD-214 AD-214 Details
USL-311 USL-311 Ligand Pharmaceuticals Inc Details
PF-06747143 PF-06747143 Pfizer Pharmaceuticals Ltd (China) Details
LEO-35299 LEO-35299 Leo Pharma A/S Details
GMI-1359 GMI-1359 Glycomimetics Pharmaceutical Details
JVS-100 SRX-100; ACRX-100; GP-51801; GP51801; JVS-100 Cleveland Clinic Details
Balixafortide POL-6326 Phase 1 Clinical Polyphor Ltd Breast Neoplasms Details
LY-2510924 T-134; LY-2510924 Eli Lilly And Company Details
Mavorixafor AMD-11070; X4P-001-IO; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081 Phase 3 Clinical Genzyme Corp HIV Infections; WHIM syndrome; Carcinoma, Renal Cell; Neutropenia; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma Details
CGT-1881 CGT1881; CGT-1881 Phase 1 Clinical Cgenetech(Suzhou China) Co Ltd Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin Details
68Ga-Pentixather 68Ga-Pentixather Phase 1 Clinical Peking Union Medical College Hospital Multiple Myeloma Details
[68Ga]Pentixafor Phase 2 Clinical The University Of Iowa Leukemia; Multiple Myeloma; Central Nervous System Neoplasms; Lymphoma Details
PTX-9908 PTX-9908 Phase 2 Clinical Pertinax Therapeutics Carcinoma, Hepatocellular Details
MSX-122 Q-122; WZ-40; MSX-122 Phase 2 Clinical Altiris Therapeutics Solid tumours; Hot Flashes Details
Ulocuplumab MDX-1338; BMS-936564 Phase 2 Clinical Bristol-Myers Squibb Company Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
MB-1707 MB-1707 Phase 1 Clinical Mainline Biosciences Inc Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Motixafortide BKT-140; BL-8040; TF-14016; TN-14003; 4F-Benzoyl-TN14003 Phase 3 Clinical Biokine Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Esophageal Neoplasms; Leukemia, Lymphoid; Pancreatic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message